Wed 12 Oct 2016 In: New Zealand Daily News View at Wayback View at NDHA
Pharmac has announced it is adding a new HIV drug to its list of Anti-Retroviral drugs. The relatively new drug Dolutegravir will be available from 1 November and was approved by medsafe in 2014. It is in the class of Integrase Strand Inhibitors (INSTI) which make up four of the five recommended regimens for the initial treatment of HIV according to US Treatment Guidelines. Executive Director of Body Positive, Mark Fisher says “Body Positive is thankful to Pharmac for adding Dolutegravir ( Trivicay) to its list of Anti-Retroviral for the treatment of HIV effective 1st November 2016”. For anyone interested in the drug, Fisher says “We recommend that people talk with their specialist about this new treatment option and consider whether this would be a good choice for them.”
Credit: GayNZ.com Daily News staff
First published: Wednesday, 12th October 2016 - 1:23pm